Otsuka Pharmaceutical Co., Ltd. entered into a definitive merger agreement to acquire Jnana Therapeutics Inc., for $800 million, as well as up to an additional $325 million in development and regulatory milestones. Jnana will become a wholly owned subsidiary through Otsuka’s subsidiary, Otsuka America, Inc. The acquisition is expected to be completed in fiscal 3Q24, subject to customary closing conditions.   Jnana’s drug discovery approach is enabled by RAPID – the company&#8...